Once-weekly semaglutide showed sustained HbA1c reductions and weight loss over 12 months in Japanese T2D patients in real-world practice, confirming clinical trial findings in an Asian population.
12-month Japanese confirmationReal-world Japanese data confirms semaglutide maintains blood sugar and weight benefits throughout a full year of treatment
What the researchers found
Once-weekly semaglutide: sustained HbA1c reduction and weight loss over 12 months in Japanese T2D real-world practice, consistent with clinical trial data. Safe and effective in Asian population.
Why it matters
Japanese prescribers need local real-world data. This confirms semaglutide works as expected in Japanese patients beyond clinical trial settings.
How the study worked
Real-world observational study of once-weekly semaglutide effectiveness and safety in Japanese T2D patients over 12 months.
What this study cannot tell us
Observational. No comparator. Japanese-specific outcomes may not generalize to other Asian populations.
How to read the evidence
Real-world observational study. Consistent with global clinical trial data.
When this study was published
Published in 2025.
The bigger picture
Real-world evidence from Japan confirms the global effectiveness of semaglutide across diverse populations.
Questions still open
- How do Japanese real-world results compare to clinical trial outcomes?
- Are there Japanese-specific adverse effect patterns?
- Would tirzepatide show similar real-world results in Japan?
Common questions
Does semaglutide work well for Japanese patients?
Are there different side effects in Japanese patients?
Read the original research
Effectiveness and Safety of Once-Weekly Semaglutide in Japanese Patients with Type 2 Diabetes: A Retrospective Observational Multicenter Study (ORIGAMI Study).
Diabetes therapy : research, treatment and education of diabetes and related disorders, 17(1), 93-111
Citation
Iwata, Yoko; Yoshikawa, Fukumi; Saito, Manabu; Fuchigami, Ayako; Sato, Genki; Saiki, Atsuhito; Ichijyo, Takamasa; Sato, Nobuyuki; Ohashi, Tadamasa; Hirose, Takahisa; Uchino, Hiroshi. (2026). Effectiveness and Safety of Once-Weekly Semaglutide in Japanese Patients with Type 2 Diabetes: A Retrospective Observational Multicenter Study (ORIGAMI Study).. Diabetes therapy : research, treatment and education of diabetes and related disorders, 17(1), 93-111. https://doi.org/10.1007/s13300-025-01790-z